Bellvitge University Hospital

Running trials

• Not yet recruiting

  A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis

  NCT07335562· Phase 3· Juno Therapeutics, Inc., a Bristol-Myers Squibb Company· Source

• Not yet recruiting

  A Study to Learn How Well People With Bronchiectasis Tolerate Continued Treatment With Verducatib After Earlier Studies (AIRTIVITY®-ON)

  NCT07915219· Phase 3· Boehringer Ingelheim· Source

• Not yet recruiting

  A study to compare heart failure medicines in one combined pill with usual care.

  2026-526510-90-00· Phase 3· Institut De Recherches Internationales Servier IRIS· Source

• Not yet recruiting

  A Study to Test Whether BI 3810477 Helps People With Idiopathic Pulmonary Fibrosis When Taken With or Without Standard Treatment

  NCT07926321· Phase 2· Boehringer Ingelheim· Source

• Not yet recruiting

  A Study of Lebrikizumab in Adults and Adolescents With Face and Neck Atopic Dermatitis

  NCT07873801· Phase 3· Almirall, S.A.· Source

• Not yet recruiting

  To Evaluate the Long-term Safety and Tolerability of Acoramidis in Participants With Newly Diagnosed ATTR-CM (ACT-EARLY OLE)

  NCT07116473· Phase 3· Eidos Therapeutics, a BridgeBio company· Source

• Recruiting

  Study of an Injectable Regimen of GS-3242 with Lenacapavir Compared to Biktarvy in People New to HIV-1 Treatment

  2026-526026-40-00· Phase 2/3· Gilead Sciences Inc.· Source

• Recruiting

  Albuminuria Reduction Trial and Investigation with Survodutide Treatment in CKD (ARTIST-CKD)

  2025-525068-13-00· Phase 2· Universitair Medisch Centrum Groningen· Source

• Recruiting

  A Study of the Long-term Safety and Efficacy of Danicamtiv in Adults with Symptomatic Genetic and Familial Dilated Cardiomyopathy (KINSHIP-OLE).

  2026-526139-20-00· Phase 3· Kardigan Inc.· Source

• Recruiting

  Holistic Assessment and Remote Digital MONitoring of mYasthenia Gravis Via MyoSense 360

  NCT07323316· Ad scientiam· Source

• Recruiting

  Study evaluating the efficacy and safety of daridorexant in patients with major depressive disorder and insomnia.

  2025-524794-16-00· Phase 4· Fundacio Institut D'Investigacio Biomedica De Bellvitge IDIBELL· Source

• Recruiting

  A Study to Evaluate The Long-Term Safety And Efficacy of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis

  NCT07465289· Phase 3· UCB Biopharma SRL· Source

• Not yet recruiting

  A Phase 2, randomized, double-blind, placebo-controlled trial to evaluate the efficacy, safety, and tolerability of CRD-4730 in patients with heart failure with reduced ejection fraction (HFREF) (CALIBRATE-HF)

  2025-525033-31-00· Phase 2· Cardurion Pharmaceuticals Inc.· Source

• Recruiting

  A Phase IIb Study to Evaluate AZD8965 in Participants with Idiopathic Pulmonary Fibrosis (IPF)

  2025-525016-41-00· Phase 2· AstraZeneca AB· Source

• Recruiting

  Study of Lenacapavir, Teropavimab, and Zinlirvimab Versus Cabotegravir and Rilpivirine in Virologically Suppressed Adults With HIV-1 on Oral Daily Antiretroviral Therapy

  2025-524335-39-00· Phase 3· Gilead Sciences Inc.· Source

• Recruiting

  A Study of the Long-term Safety and Efficacy of Danicamtiv in Adults With Symptomatic Genetic and Familial Dilated Cardiomyopathy

  NCT07771465· Phase 3· Kardigan, Inc.· Source

• Recruiting

  A study to find out if enfortumab vedotin given with pembrolizumab helps people with muscle-invasive bladder cancer keep their bladder.

  2025-524488-18-00· Phase 2· Astellas Pharma Global Development Inc.· Source

• Recruiting

  ReVeRA-301: Etripamil in Atrial Fibrillation Phase 3

  NCT06716021· Phase 3· Milestone Pharmaceuticals Inc.· Source

• Recruiting

  A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis

  NCT07497087· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  A study to check whether adding RUTI® to standard BCG treatment for high-risk early-stage bladder cancer is safe and how it changes the body’s defenses, with participants randomly receiving RUTI® or a look-alike treatment.

  2026-525897-20-00· Phase 1· Laboratorio Reig Jofre S.A.· Source

• Recruiting

  A Study to Find an Efficacious and Safe Dose of CHF10067 (Zampilimab) in Participants With Idiopathic Pulmonary Fibrosis

  NCT07516951· Phase 2· Chiesi Farmaceutici S.p.A.· Source

• Recruiting

  Spanish Prospective Registry of Hydra THV for Transcatheter Aortic Valve Implantation

  NCT07566624· Fundación EPIC· Source

• Recruiting

  Cardiac Magnetic Resonance and Echocardiography Study With Acoramidis

  NCT07695701· Phase 4· Eidos Therapeutics, a BridgeBio company· Source

• Not yet recruiting

  Evaluation of Calcified Coronary Lesion Preparation With the Naviscore Scoring Balloon

  NCT07650578· University of Mons· Source

• Recruiting

  A Study to Investigate Cabotegravir Ultra Long-Acting (CAB ULA) Plus Rilpivirine Ultra Long-Acting (RPV ULA) in Adults and Adolescents With HIV Who Are Virologically Suppressed

  NCT07650916· Phase 3· ViiV Healthcare· Source

• Recruiting

  A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents with Severe Uncontrolled Asthma (SOLAIRIA-1)

  2025-524040-35-00· Phase 3· Generate Biomedicines Inc.· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis

  NCT07463521· Phase 3· UCB Biopharma SRL· Source

• Recruiting

  A Phase 3 Trial of K-924 HD in Participants with Hypercholesterolemia with Inadequate Response to EU-Marketed Pitavastatin 4 mg

  2025-523739-20-00· Phase 3· Kowa Co. Ltd.· Source

• Recruiting

  A Substudy of LY4256984 in Participants With Sporadic Amyotrophic Lateral Sclerosis

  NCT07571174· Phase 1· Eli Lilly and Company· Source

• Recruiting

  A Master Protocol (OLMP): A Study of LY4256984 in Participants With Amyotrophic Lateral Sclerosis (ALS)

  NCT07571200· Phase 1· Eli Lilly and Company· Source

• Recruiting

  Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS (PREVAiLS)

  2025-524002-16-00· Phase 3· Ferrer Internacional S.A.· Source

• Not yet recruiting

  REACTION-VAD Trial: Remote Exercise Training Via Telemedicine in Patients With Long-Term Ventricular Assist Devices

  NCT07611188· Puerta de Hierro University Hospital· Source

• Not yet recruiting

  Retinal Ganglion Cell Neuroprotection Under Prostaglandin Analogues

  NCT07074782· Association for Innovation and Biomedical Research on Light and Image· Source

• Recruiting

  A Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety When Given Before Symptoms Appear in Babies With Genetically Diagnosed Spinal Muscular Atrophy (SMA)

  NCT07221669· Phase 3· Biogen· Source

• Recruiting

  A clinical trial to find out how well LOU064 (remibrutinib) works and how safe it is for people with secondary progressive multiple sclerosis

  2025-521546-23-00· Phase 3· Novartis Pharma AG· Source

• Recruiting

  Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants with Chronic Spontaneous Urticaria

  2025-522878-36-00· Phase 3· Celldex Therapeutics Inc.· Source

• Not yet recruiting

  PRIME Trial - Primary Respiratory Infection and Microbiological Eradication Trial

  2025-524454-34-00· Phase 4· Fundacio Institut De Recerca De L'Hospital De La Santa Creu I Sant Pau· Source

• Not yet recruiting

  Efficacy and Safety of Daridorexant in Patients With Major Depressive Disorder and Insomnia

  NCT07555743· Phase 4· Institut d'Investigació Biomèdica de Bellvitge· Source

• Enrolling by invitation

  A Long-Term Follow-Up Study of Subjects Completing the AU-011-301(CoMpass) for Early Choroidal Melanoma

  NCT07338968· Phase 3· Aura Biosciences· Source

• Recruiting

  A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease

  NCT07326709· Phase 3· Novartis Pharmaceuticals· Source

• Recruiting

  A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS)

  NCT07282574· Phase 2· Hoffmann-La Roche· Source

• Recruiting

  AURA-IPF: A Randomized Phase 2 Study to Evaluate the Safety and Efficacy of AP02 (Nintedanib Solution) in IPF

  NCT07194382· Phase 2· Avalyn Pharma Inc.· Source

• Not yet recruiting

  Combined impact of cardiovascular polypill treatment and a specific nurse education program on adherence to therapy in patients with ACS: a randomized study

  2025-524751-32-00· Phase 4· Fundacion Epic· Source

• Recruiting

  A Study of the Efficacy and Safety of Danicamtiv in Participants with Symptomatic Genetic and Familial Dilated Cardiomyopathy.

  2025-522553-19-00· Phase 2/3· Kardigan Inc.· Source

• Recruiting

  A Study to Test if Tenecteplase Helps People to Recover From an Acute Stroke When Given More Than 4.5 Hours After the Person Was Last Seen Well

  NCT07361302· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  A Study of the Efficacy and Safety of Danicamtiv in Participants With Symptomatic Genetic and Familial Dilated Cardiomyopathy

  NCT07210723· Phase 2/3· Kardigan, Inc.· Source

• Recruiting

  A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)

  NCT07202546· Phase 2· ViiV Healthcare· Source

• Recruiting

  TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy

  NCT07223203· Phase 3· Alnylam Pharmaceuticals· Source

• Recruiting

  Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS

  NCT07322003· Phase 3· Prilenia· Source

• Not yet recruiting

  Comparison of Transmesocolic Versus Retromesenteric Reconstruction in Cephalic Duodenopancreatectomy (FAST Trial)

  NCT07368218· Hospital Universitari de Bellvitge· Source

Showing 50 of 208.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Heart failure15 recruiting
• Coronary artery disease8 recruiting
• ALS (motor neurone disease)7 recruiting
• Amyloidosis6 recruiting
• Stroke6 recruiting
• Aortic stenosis5 recruiting
• Dilated cardiomyopathy5 recruiting
• HIV5 recruiting
• Myasthenia gravis5 recruiting
• Bronchiectasis4 recruiting
• Idiopathic pulmonary fibrosis4 recruiting
• Macular degeneration4 recruiting
• Atrial fibrillation3 recruiting
• Bladder cancer3 recruiting
• Depression3 recruiting
• Multiple sclerosis3 recruiting
• Obesity3 recruiting
• Pancreatic cancer3 recruiting
• Prostate cancer3 recruiting
• Asthma2 recruiting
• Atopic dermatitis (eczema)2 recruiting
• Chronic kidney disease2 recruiting
• COPD2 recruiting
• Gastric and oesophageal cancer2 recruiting
• Huntington's disease2 recruiting
• Insomnia2 recruiting
• Melanoma2 recruiting
• Myocarditis2 recruiting
• Neuroendocrine tumours2 recruiting
• Systemic sclerosis (scleroderma)2 recruiting
• ANCA-associated vasculitis1 recruiting
• Aortic aneurysm1 recruiting
• Bipolar disorder1 recruiting
• Childhood cancers1 recruiting
• Chronic spontaneous urticaria1 recruiting
• Colorectal cancer1 recruiting
• Crohn's disease1 recruiting
• Cystic fibrosis1 recruiting
• Dermatomyositis and polymyositis (myositis)1 recruiting
• Diabetic eye disease1 recruiting
• Endometrial cancer1 recruiting
• Epilepsy1 recruiting
• Familial hypercholesterolaemia1 recruiting
• Gastroparesis1 recruiting
• Glaucoma1 recruiting
• High blood pressure1 recruiting
• Hypertrophic cardiomyopathy1 recruiting
• Hypothyroidism1 recruiting
• Lung cancer1 recruiting
• Metastatic breast cancer1 recruiting
• Migraine1 recruiting
• Nephrotic syndrome1 recruiting
• Ovarian cancer1 recruiting
• Spinal muscular atrophy1 recruiting
• Type 2 diabetes1 recruiting
• Ulcerative colitis1 recruiting

Closed trials

• Active, not recruiting

  An Extension Study to Investigate the Long-term Safety and Tolerability of Itepekimab in Adult Participants With Inadequately Controlled Chronic Rhinosinusitis With Nasal Polyps

  NCT07424144· Phase 3· Sanofi· Source

• Recruiting

  Study is to Assess the Safety and Tolerability of VTx-002 in Participants With ALS

  NCT07287397· Phase 1/2· Vector Y Therapeutics· Source

• Active, not recruiting

  Study of BLU-808 in Chronic Inducible Urticaria (CIndU) and Chronic Spontaneous Urticaria (CSU)

  NCT06931405· Phase 2· Blueprint Medicines Corporation· Source

• Completed

  A Phase 2b, Multicenter, Randomized, Double-blind, Placebo- and Active-controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of JNJ-95475939 for the Treatment of Participants with Moderate to Severe Atopic Dermatitis

  2024-517814-13-00· Phase 2· Janssen Cilag International· Source

• Completed

  Study of Oral Weekly GS-1720 and GS-4182 Versus Biktarvy in People With HIV-1 Who Are Virologically Suppressed

  NCT06544733· Phase 2/3· Gilead Sciences Inc.· Source

• Recruiting

  A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease

  NCT06717698· Phase 2· Novo Nordisk A/S· Source

• Completed

  Efficacy, Safety and Tolerability of BHV-7000 in Subjects with Idiopathic Generalized Epilepsy with Generalized Tonic-clonic Seizures – SHINE

  NCT06425159· Phase 2/3· Biohaven Therapeutics Ltd.· Source

• Completed

  Sapphire 3 CTO Study

  NCT06358508· OrbusNeich· Source

• Completed

  Phase 2 study to evaluate the efficacy and safety of GSK3915393 in participants with Idiopathic Pulmonary Fibrosis (IPF)

  NCT06317285· Phase 2· Glaxosmithkline Research & Development Limited· Source

• Completed

  A study to test whether BI 1839100 improves cough in people with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis

  2023-510249-79-00· Phase 2· Boehringer Ingelheim International GmbH· Source

• Completed

  A Study to Test Whether BI 1819479 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)

  NCT06335303· Phase 2· Boehringer Ingelheim· Source

• Completed

  A Study to Learn About How Well BAY3283142 Works and Its Safety in Participants With Chronic Kidney Disease

  NCT06522997· Phase 2· Bayer· Source

• Completed

  A randomized, double-blind, dose-ranging, placebo-controlled study to evaluate the efficacy and safety of PLN-74809 (bexotegrast) for the treatment of idiopathic pulmonary fibrosis (BEACON-IPF)

  2023-506185-31-00· Phase 2/3· Pliant Therapeutics Inc.· Source

• Completed

  Validation of a Score for Supplementation Needs of Vitamins, Micronutrients and Proteins After Bariatric Surgery

  NCT07268209· Hospital Universitari de Bellvitge· Source

• Completed

  Evaluating efficacy and safety of switching a boosted protease inhibitor to fostemsavir in PLWH with limited therapeutic options (FOST Switch)

  2023-504192-25-00· Phase 4· NEAT ID Foundation· Source

• Completed

  A Study to Learn How Safe Starting Vericiguat at a Dose of 5 Milligrams is in Participants With Chronic Heart Failure With Reduced Ejection Fraction

  NCT06195930· Phase 2· Bayer· Source

• Completed

  Comparison of three short rifamycin-based regimens to treat latent tuberculosis in patients with end-stage kidney disease.

  2023-506432-32-00· Phase 4· Bellvitge University Hospital· Source

• Completed

  A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and Placebo

  NCT06131372· Phase 2· Novo Nordisk A/S· Source

• Completed

  A Phase 1b, Open-Label, Multiple Ascending Dose, Multicenter Study of VRG50635 in Participants With Sporadic and Familial Amyotrophic Lateral Sclerosis Followed by Long-Term Treatment

  2023-506509-21-00· Phase 1· Verge Genomics· Source

• Active, not recruiting

  A Phase 2 Study to Evaluate DNTH103 in Adults With Generalized Myasthenia Gravis (MAGIC)

  NCT06282159· Phase 2· Dianthus Therapeutics· Source

• Completed

  A Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Non-cystic Fibrosis Bronchiectasis

  NCT06280391· Phase 2· Sanofi· Source

• Completed

  THE ANTES B+ STUDY: AN OPEN-LABEL, PRAGMATIC, RANDOMIZED, CONTROLLED TRIAL OF TRIPLE THERAPY VERSUS LABA-LAMA COMBINATION TO IMPROVE CLINICAL CONTROL IN HIGH-RISK GOLD B PATIENTS (B+)

  2023-507304-32-00· Phase 4· Fundacio Privada Mon Clinic Barcelona· Source

• Completed

  Cough Reduction in IPF With Nalbuphine ER

  NCT05964335· Phase 2· Trevi Therapeutics· Source

• Completed

  Impact of the Implementation of a Telemedicine Program on Patients Diagnosed With Asthma

  NCT06116292· Hospital Universitari de Bellvitge· Source

• Active, not recruiting

  MAXPIRe: Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis (IPF)

  NCT06132256· Phase 2· Syndax Pharmaceuticals· Source

• Terminated

  A Clinical Study of MK-6194 for the Treatment of Vitiligo (MK-6194-007)

  NCT06113328· Phase 2· Merck Sharp & Dohme LLC· Source

• Terminated

  Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809) for Idiopathic Pulmonary Fibrosis

  NCT06097260· Phase 2· Pliant Therapeutics, Inc.· Source

• Active, not recruiting

  Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)

  NCT06122779· Phase 2· Bristol-Myers Squibb· Source

• Completed

  Proof of Concept Treatment Study of Orally Administered VH4004280 or VH4011499 in HIV-1 Infected Adults

  NCT06039579· Phase 2· ViiV Healthcare· Source

• Completed

  A Phase 3, Double-blind Maintenance Study Assessing Rocatinlimab in Moderate-to-severe AD (ROCKET-ASCEND)

  NCT05882877· Phase 3· Amgen Inc.· Source

• Completed

  A Trial to Evaluate the Efficacy and Safety of Different Doses of LEO 138559 in Adults With Moderate-to-severe Atopic Dermatitis

  NCT05923099· Phase 2· LEO Pharma· Source

• Completed

  A Study to Evaluate the Efficacy and Safety of Vixarelimab Compared with Placebo in Patients with Idiopathic Pulmonary Fibrosis and in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease

  2022-502828-42-00· Phase 2· Genentech Inc.· Source

• Completed

  A Phase 2b, Randomized, Double-blind Study of Redasemtide (S-005151) in Adult Participants With Acute Ischemic Stroke

  NCT05953480· Phase 2· Shionogi· Source

• Completed

  Phase 2b Study to Assess Efficacy and Safety of Batoclimab in Adult Participants with Active CIDP.

  2024-512646-42-00· Phase 2· Immunovant Sciences GmbH· Source

• Completed

  A Study to Assess Treat-to-Target and Dosing Flexibility of Oral Upadacitinib Tablets in Adult Participants With Moderate to Severe Atopic Dermatitis

  NCT05507580· Phase 4· AbbVie· Source

• Completed

  A Phase 2 Study of the Effects of Ponsegromab on Health-Related Quality of Life and Safety in Patients With Heart Failure (GARDEN-TIMI 74)

  NCT05492500· Phase 2· Pfizer Inc.· Source

• Completed

  A Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate Mavacamten in Adults with Cardiomyopathy

  NCT05582395· Phase 3· Myokardia Inc.· Source

• Completed

  Tigulixostat, Phase 3 Study, Allopurinol Controlled in Gout Patients

  NCT05586971· Phase 3· LG Chem· Source

• Completed

  Vamikibart in Participants With Uveitic Macular Edema

  NCT05642325· Phase 3· Hoffmann-La Roche· Source

• Terminated

  Study to Investigate the Long-term Safety of FAB122 in Patients With Amyotrophic Lateral Sclerosis

  NCT05866926· Phase 3· Ferrer Internacional S.A.· Source

• Completed

  A Study Evaluating the Effects of GLPG3667 Given as Oral Treatment for up to 24 Weeks in Adults With Dermatomyositis

  NCT05695950· Phase 2· Lakefront Biotherapeutics NV· Source

• Active, not recruiting

  A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE

  NCT05702034· Phase 3· Janssen Research & Development, LLC· Source

• Terminated

  A Study of LY3540378 in Participants With Worsening Chronic Heart Failure With Preserved Ejection Fraction (HFpEF)

  NCT05592275· Phase 2· Eli Lilly and Company· Source

• Completed

  A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke

  NCT05686070· Phase 3· Bayer· Source

• Completed

  Investigation of the ALLEGRA THV System With a New Delivery System in Patients With Aortic Stenosis or Failed Surgical Bioprosthesis

  NCT05478161· NVT GmbH· Source

• Terminated

  A Study of TCD601 (Siplizumab) in New Onset Type 1 Diabetes Patients

  NCT06025110· Phase 2· ITB-Med LLC· Source

• Terminated

  Study of M5049 in DM and PM Participants (NEPTUNIA)

  NCT05650567· Phase 2· EMD Serono Research & Development Institute, Inc.· Source

• Completed

  Efficacy of [18F]Florbetaben PET for Diagnosis of Cardiac AL Amyloidosis

  NCT05184088· Phase 3· Lantheus Germany GmbH· Source

• Completed

  A study to learn how well the study treatment asundexian works and how safe it is compared to apixaban to prevent stroke or systemic embolism in people with irregular and often rapid heartbeat (atrial fibrillation), and at risk for stroke

  NCT05643573· Phase 3· Bayer AG· Source

• Completed

  Phase 2 Study of EDG-5506 in Becker Muscular Dystrophy (GRAND CANYON)

  NCT05291091· Phase 2· Edgewise Therapeutics, Inc.· Source

Showing 50 of 103.

Conditions

Diseases this institution publishes on or runs trials for.

• Lupus (SLE)18 works · 2 trials
• ALS (motor neurone disease)16 works · 15 trials
• Amyloidosis15 works · 11 trials
• Idiopathic pulmonary fibrosis13 works · 20 trials
• Bronchiectasis12 works · 6 trials
• Myocarditis11 works · 2 trials
• Giant cell arteritis7 works · 0 trials
• Ankylosing spondylitis7 works · 0 trials
• Myasthenia gravis7 works · 10 trials
• Dilated cardiomyopathy7 works · 5 trials
• ANCA-associated vasculitis5 works · 1 trial
• Cushing's syndrome5 works · 0 trials
• Alopecia areata4 works · 1 trial
• Myotonic dystrophy3 works · 0 trials